Posts tagged as: AEZS news back to homepage
 |
Aeterna Zentaris Stock Chart Analysis Video(0) Three straight days of closing ahead has the AEterna Zentaris chart on watch for continued upward pressure. Shares rose 8.5 percent on Tuesday to close near the high of the day on increased volume, which is a bullish sign as the stock nears resistance. Shares traded as low as $1.75 last week, but have recovered to close on Tuesday at $2.16 on Read More |
|
Aeterna Zentaris Continues Pursuing Drug Development for Multiple Myeloma(0) The path to bring a new cancer drug to market can certainly be a long and bumpy road full of twists and turns. It was about one month ago that the news hit of Aeterna Zentaris (TSX: AEZ)(NASDAQ: AEZS) and Keryx Biopharmaceuticals (NASDAQ: KERX) terminating their license agreement with respect to perifosine, an Akt inhibiting oral anticancer compound; giving back full North American rights to Aeterna. Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
